Full Text View
Tabular View
No Study Results Posted
Related Studies
Efficacy, Safety, and Tolerability of SAR231893 (REGN668) in Patients With Persistent Moderate to Severe Eosinophilic Asthma
This study has been completed.
Study NCT01312961   Information provided by Sanofi

First Received on March 9, 2011.   Last Updated on January 30, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Asthma
Additional conditions recognized in this trial
Pulmonary Eosinophilia
More general conditions related to this trial
Bronchial Diseases
Eosinophilia
Hematologic Diseases
Hypereosinophilic Syndrome
Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Leukocyte Disorders
Lung Diseases
Lung Diseases, Obstructive
Respiratory Hypersensitivity
Respiratory Tract Diseases
Interventions listed in this trial
SAR231893 (REGN668)
placebo
Sponsors listed in this trial
Sanofi
Regeneron Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services